First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

导出原文传递

翻译打印收藏纠错

作者： Hidalgo, Manuel ^[1] ; Martinez-Garcia, Maria ^[2] ; Le Tourneau, Christophe ^[3] ; Massard, Christophe ^[4] ; Garralda, Elena ^[5] ; Boni, Valentina ^[6] ; Taus, Alvaro ^[7] ; Albanell, Joan ^[8] ; Sablin, Marie-Paule ; Alt, Marie ; Bahleda, Ratislav ; Varga, Andrea ; Boetsch, Christophe ; Franjkovic, Izolda ; Heil, Florian ; Lahr, Angelika ; Lechner, Katharina ; Morel, Anthony ; Nayak, Tapan ; Rossomanno, Simona ; Smart, Kevin ; Stubenrauch, Kay ; Krieter, Oliver

作者单位： Roche Innovat Ctr Munich, Penzberg, Germany ^[1] Gustave Roussy, Dept Drug Dev, Villejuif, France ^[2] Hosp del Mar, Med Oncol Dept, Barcelona, Spain ^[3] HM Sanchinarro, START Madrid CIOCC, Madrid, Spain ^[4] CNIO, Madrid, Spain ^[5] Inst Curie, Dept Med Oncol, St Cloud, France ^[6] Roche Innovat Ctr Basel, Basel, Switzerland ^[7] Roche Innovat Ctr Welwyn, Welwyn Garden City, Herts, England ^[8]

发布时间 2019-04-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览5

Clinical cancer research

2018年24卷7期

1536-1545页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除